Omada Health (OMDA)
Market Price (9/27/2026): $19.75 | Market Cap: $1.2 BilSector: Health Care | Industry: Health Care Technology
Omada Health (OMDA)
Market Price (9/27/2026): $19.75Market Cap: $1.2 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 48% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -90% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -0.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.1% Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 250x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 50x, P/EPrice/Earnings or Price/(Net Income) is 273x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.6% Key risksOMDA key risks include [1] a significant revenue concentration with a few key customers and [2] ongoing operating and net losses. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 48% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -90% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -0.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.1% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 250x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 50x, P/EPrice/Earnings or Price/(Net Income) is 273x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.6% |
| Key risksOMDA key risks include [1] a significant revenue concentration with a few key customers and [2] ongoing operating and net losses. |
Qualitative Assessment
AI Analysis | Feedback
Omada Health (OMDA) stock has gained about 10% since 5/31/2026 because of the following key factors:
1. Robust Fiscal Q2 2026 Financial Performance and Raised Full-Year Outlook.
Omada Health reported exceptional fiscal Q2 2026 results (period ending June 30, 2026), demonstrating significant year-over-year growth and a move to profitability. Revenue increased by 43% to $88 million compared to $61 million in fiscal Q2 2025. The company achieved a net income of $5 million, a substantial improvement from a $5 million net loss in the prior year's second quarter. Adjusted EBITDA also turned positive at $11 million, up from a $0.2 million loss in fiscal Q2 2025. Following these strong results, Omada Health raised its full-year fiscal 2026 revenue guidance to a range of $334 million to $340 million, an increase from the previous guidance of $322 million to $330 million. The adjusted EBITDA guidance for fiscal 2026 was also elevated to $21 million to $27 million, significantly higher than the prior range of $14 million to $20 million.
2. Strategic Alignment with Growing GLP-1 Therapy Demand.
Omada Health's strategic positioning to support the burgeoning GLP-1 (glucagon-like peptide-1) therapy market has been a significant growth driver. The company offers programs that assist patients undergoing GLP-1 therapy, acting as a "gatekeeper or step-therapy program" for health plans and employers seeking to manage the escalating costs associated with these weight-loss medications. This strategy capitalizes on a rapidly expanding market, as GLP-1 drugs represented over 11% of pharmacy claims in 2026, an increase from 7% in 2023.
Show more
Omada Health (OMDA) stock has gained about 10% since 5/31/2026 because of the following key factors:
1. Robust Fiscal Q2 2026 Financial Performance and Raised Full-Year Outlook.
Omada Health reported exceptional fiscal Q2 2026 results (period ending June 30, 2026), demonstrating significant year-over-year growth and a move to profitability. Revenue increased by 43% to $88 million compared to $61 million in fiscal Q2 2025. The company achieved a net income of $5 million, a substantial improvement from a $5 million net loss in the prior year's second quarter. Adjusted EBITDA also turned positive at $11 million, up from a $0.2 million loss in fiscal Q2 2025. Following these strong results, Omada Health raised its full-year fiscal 2026 revenue guidance to a range of $334 million to $340 million, an increase from the previous guidance of $322 million to $330 million. The adjusted EBITDA guidance for fiscal 2026 was also elevated to $21 million to $27 million, significantly higher than the prior range of $14 million to $20 million.
2. Strategic Alignment with Growing GLP-1 Therapy Demand.
Omada Health's strategic positioning to support the burgeoning GLP-1 (glucagon-like peptide-1) therapy market has been a significant growth driver. The company offers programs that assist patients undergoing GLP-1 therapy, acting as a "gatekeeper or step-therapy program" for health plans and employers seeking to manage the escalating costs associated with these weight-loss medications. This strategy capitalizes on a rapidly expanding market, as GLP-1 drugs represented over 11% of pharmacy claims in 2026, an increase from 7% in 2023.
3. Expansion of Channel Partnerships and Introduction of New Programs.
Operational highlights in the period included the expansion of key channel partnerships and the launch of new care offerings. Omada Health broadened its collaboration with Health Care Services Corporation (HCSC), extending its Prevention & Weight Health and Hypertension Management programs to an additional 1.5 million covered lives across multiple states. Furthermore, the company initiated the first deployment of its cholesterol management program in July 2026. Recent partnerships with major pharmacy benefit managers, including Optum and Caremark, alongside its integration into Lilly's employer platform for GLP-1 care, are expected to further boost active member enrollment.
4. Positive Analyst Sentiment and Upgraded Price Targets.
Analyst coverage has reflected a bullish outlook on Omada Health's prospects. The stock holds a consensus "Moderate Buy" rating from fourteen analysts, with eleven issuing a buy recommendation. The average 12-month price target is set at $26.67, with several firms, including JPMorgan and Citizens Jmp, issuing targets as high as $30 and $32, respectively. In July 2026, BTIG initiated coverage with a Buy rating and a $30 price target, and in August 2026, Barclays raised its target price from $20 to $25, indicating growing confidence in the company's valuation.
Show less
Stock Movement Drivers
Fundamental Drivers
The 9.4% change in OMDA stock from 5/31/2026 to 9/26/2026 was primarily driven by a 9.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312026 | 9262026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.97 | 19.66 | 9.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 283 | 310 | 9.3% |
| P/S Multiple | 3.7 | 3.8 | 1.4% |
| Shares Outstanding (Mil) | 59 | 60 | -1.3% |
| Cumulative Contribution | 9.4% |
Market Drivers
5/31/2026 to 9/26/2026| Return | Correlation | |
|---|---|---|
| OMDA | 9.4% | |
| Market (SPY) | 2.2% | 20.8% |
| Sector (XLV) | 14.7% | 27.5% |
Fundamental Drivers
The 60.1% change in OMDA stock from 2/28/2026 to 9/26/2026 was primarily driven by a 100.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 9262026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.28 | 19.66 | 60.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 154 | 310 | 100.7% |
| P/S Multiple | 3.8 | 3.8 | -0.2% |
| Shares Outstanding (Mil) | 48 | 60 | -20.0% |
| Cumulative Contribution | 60.1% |
Market Drivers
2/28/2026 to 9/26/2026| Return | Correlation | |
|---|---|---|
| OMDA | 60.1% | |
| Market (SPY) | 13.0% | 25.3% |
| Sector (XLV) | 7.5% | 30.2% |
Fundamental Drivers
The -17.0% change in OMDA stock from 8/31/2025 to 9/26/2026 was primarily driven by a -52.5% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9262026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.69 | 19.66 | -17.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 142 | 310 | 118.5% |
| P/S Multiple | 8.0 | 3.8 | -52.5% |
| Shares Outstanding (Mil) | 48 | 60 | -20.0% |
| Cumulative Contribution | -17.0% |
Market Drivers
8/31/2025 to 9/26/2026| Return | Correlation | |
|---|---|---|
| OMDA | -17.0% | |
| Market (SPY) | 20.9% | 24.3% |
| Sector (XLV) | 26.4% | 21.4% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/26/2026| Return | Correlation | |
|---|---|---|
| OMDA | ||
| Market (SPY) | 77.8% | 21.0% |
| Sector (XLV) | 34.7% | 18.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OMDA Return | - | - | - | - | -31% | 25% | -14% |
| Peers Return | -51% | -54% | 7% | 2% | -16% | 44% | -70% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| OMDA Win Rate | - | - | - | - | 29% | 56% | |
| Peers Win Rate | 27% | 38% | 50% | 40% | 35% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| OMDA Max Drawdown | - | - | - | - | - | -34% | |
| Peers Max Drawdown | -71% | -69% | -59% | -63% | -59% | -40% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, HIMS, GDRX, AMWL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/25/2026 (YTD)
How Low Can It Go
OMDA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
OMDA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Omada Health (OMDA)
Omada Health (OMDA) is a virtual care company dedicated to "bending the curve" of chronic disease by empowering individuals to make lasting health changes. The company addresses the significant and rising costs associated with managing prevalent chronic conditions such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (MSK) issues, which often lack effective, continuous support in traditional, encounter-based healthcare models. Omada provides an engaging, personalized, and integrated virtual care experience that combines human-led clinical coaching with purpose-built technology, an approach they term "Compassionate Intelligence," to improve member health outcomes and deliver value to those covering care costs.
Omada’s core offerings comprise an integrated, multi-condition care platform. Its programs include cardiometabolic support for prediabetes, diabetes, and hypertension, a dedicated physical therapy program for MSK conditions, and specialized GLP-1 Care Tracks for members utilizing glucagon-like peptide-1 agonists. Behavioral health support is also integrated across all programs. The company primarily sells its services to organizations that financially cover the cost for their populations, including employers, health plans, health systems, and pharmacy benefit managers (PBMs). Omada also leverages channel partners to extend its reach to end customers like employers.
As of early 2025, Omada serves over 2,000 customers and has supported more than one million members since its launch, with over 679,000 currently enrolled. The company demonstrates strong customer satisfaction rates, exceeding 90% in 2024, and high member engagement, with over 50% of cardiometabolic members still engaging monthly after two years. Omada has experienced substantial revenue growth, increasing by 38% to $169.8 million in 2024 and by 57% in Q1 2025. This growth is reinforced by a net dollar retention rate of 128% in 2024, though the company notes a history of net losses due to ongoing investments in its platform and programs.
AI Analysis | Feedback
Noom for chronic diseases.
A virtual Weight Watchers for managing chronic conditions like diabetes and hypertension.
AI Analysis | Feedback
- Cardiometabolic Programs: Virtual care programs designed to manage and prevent prediabetes, diabetes, and hypertension.
- Physical Therapy Program: A virtual program addressing musculoskeletal (MSK) conditions.
- GLP-1 Care Tracks: Specialized support integrated into cardiometabolic programs for members using glucagon-like peptide-1 agonists.
- Behavioral Health Support: Integrated behavioral health services offered across all Omada programs to enhance overall well-being.
AI Analysis | Feedback
Omada Health (OMDA) sells its programs primarily to other companies and entities that cover the cost for individuals. Based on the provided description, the company does not name specific customer companies. Instead, it identifies the following categories of organizations as its major customers and channel partners:
- Employers: These entities cover Omada's programs for their employees and their dependents.
- Health Systems: These entities cover Omada's programs for their patients.
- Health Plans: These entities either cover Omada's programs for a portion of their members as direct customers or act as channel partners reselling the programs.
- Pharmacy Benefit Managers ("PBMs"): These entities act as channel partners, reselling Omada's programs to their own end customers, which are typically employers.
AI Analysis | Feedback
AI Analysis | Feedback
Sean Duffy, Co-Founder & Chief Executive Officer
Sean Duffy co-founded Omada Health in 2011 with the goal of revolutionizing healthcare for chronic diseases by merging medical trends and technology. Before Omada Health, he created Excel Everest, an interactive Microsoft Excel training tool, and worked as an editor for Medgadget, a medical technology blog. He also held roles at Google and IDEO. Duffy began his journey with a background in medicine and technology, having pursued dual MD/MBA degrees at Harvard.
Steve Cook, Chief Financial Officer
Steve Cook joined Omada Health as Chief Financial Officer in 2021. He brings over a decade of experience in financial strategy, having previously served as Vice President and Head of Strategic Finance at One Medical, where he guided their strategic finance efforts through its 2020 IPO. Prior to that, Cook spent six years in finance and strategy at Salesforce.
Wei-Li Shao, President
Wei-Li Shao joined Omada Health in 2019 and serves as its President. He has over 20 years of global healthcare experience, including executive roles at Eli Lilly and Company, where he built and led biopharmaceutical and diagnostic imaging businesses in various countries, including the United States, China, and New Zealand.
Carolyn Jasik, Chief Medical Officer
Carolyn Jasik serves as the Chief Medical Officer of Omada Health. She brings expertise in clinical care and is instrumental in integrating medical best practices within Omada's virtual care programs.
Sunil Kayiti, Chief Technology Officer
Sunil Kayiti is the Chief Technology Officer at Omada Health. He is responsible for the technology and platform enhancements that support Omada's virtual care programs.
AI Analysis | Feedback
The key risks to Omada Health's business include:
-
History of Net Losses and Path to Profitability: Omada Health has a history of net losses and has not yet achieved profitability on an annual basis, which is attributed to significant investments in program and platform enhancements.
-
Reliance on Customers, Channel Partners, and Evolving Reimbursement Models: Omada Health's revenue is dependent on securing and retaining contracts with employers, health plans, health systems, pharmacy benefit managers ("PBMs"), and other entities that cover the cost of their programs for covered individuals. Changes in the willingness of these customers and channel partners to cover or resell Omada's programs, or shifts in the broader healthcare reimbursement landscape, could significantly impact the company's financial performance.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Omada Health (OMDA) over the Next 2-3 Years:
- Expansion and Adoption of GLP-1 Related Programs: Omada Health anticipates significant revenue growth from its GLP-1 Care Track, driven by employer demand to maximize the value of their GLP-1 investments. The company has launched new offerings, including GLP-1 prescribing and GLP-1 Flex Care, which provides employers with a structured way to connect eligible employees with clinical evaluation, prescribing, and ongoing medical oversight for GLP-1s alongside Omada's lifestyle and behavioral support. This initiative is expected to cater to the growing market for anti-obesity medications and associated care.
- Growth of the Multi-Condition Care Platform and New Condition Launches: Omada continues to expand the reach and depth of its integrated multi-condition care platform, which already addresses cardiometabolic conditions (prediabetes, diabetes, hypertension), musculoskeletal (MSK) conditions, and behavioral health. The launch of "Omada for Cholesterol" in February 2026 further strengthens its cardiometabolic offerings and expands the scope of its platform, allowing the company to address more prevalent and often comorbid chronic conditions.
- Customer Acquisition and Deeper Penetration within Existing Customer Accounts: Omada Health's revenue growth is also expected from acquiring new customers, which include employers, health plans, health systems, and pharmacy benefit managers (PBMs). Furthermore, the company aims for deeper penetration within its existing customer base, expanding the number of programs and members covered per account. Omada's strong customer satisfaction and high net dollar retention rates (128% in 2024) indicate successful existing relationships that can drive further expansion.
- Leveraging Artificial Intelligence (AI) for Enhanced Engagement and Program Efficacy: Omada is strategically investing in and deploying AI-powered tools, such as OmadaSpark and Meal Map, launched in 2025, to enhance member engagement and optimize care delivery. These AI-supported tools are designed to provide personalized healthcare experiences, offer 24/7 access to resources, and assist human-led care teams, ultimately contributing to better health outcomes and increased member retention, which indirectly supports revenue growth.
AI Analysis | Feedback
Share Issuance
- Omada Health completed its Initial Public Offering (IPO) in June 2025, offering 7.9 million shares at $19.00 per share.
- The IPO successfully raised $150 million for the company.
- The offering included a 30-day option for underwriters to purchase up to an additional 1.185 million shares.
Inbound Investments
- Prior to its IPO, Omada Health had raised over $500 million in total funding.
- In February 2022, the company secured $192 million through a Series E funding round, which led to its valuation as a unicorn.
Peer Outperformance in Health Care Technology
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 7.6% | 43.9% | 86.8% | CAH 377% · MCK 334% · COR 164% |
| Managed Health Care | 8 | 33.6% | -8.9% | 3.0% | OSCR 66% · HQY 30% · ELV 10% |
| Health Care Services | 20 | 20.0% | 38.9% | 2.4% | HIMS 252% · RDNT 141% · DGX 74% |
| Health Care Facilities | 24 | 2.9% | 12.1% | -1.4% | THC 273% · NHC 268% · ENSG 130% |
| Health Care Equipment | 50 | -1.8% | -1.1% | -18.6% | POCI 11475% · UFPT 375% · GKOS 205% |
| Health Care Supplies | 12 | 28.3% | -7.5% | -37.9% | LNTH 263% · HAE 52% · MMSI 20% |
| Pharmaceuticals | 63 | -9.3% | 7.3% | -43.3% | LQDA 2220% · INDV 1090% · ETON 1049% |
| Life Sciences Tools & Services | 113 | 1.4% | -8.6% | -66.0% | SNWV 1957% · NTRA 258% · MEDP 224% |
| Health Care Technology ← | 21 | -33.1% | -52.6% | -78.1% | SPOK 72% · HSTM 3% · VEEV -5% |
| Biotechnology | 374 | -11.5% | -25.5% | -79.9% | CELZ 1371% · DNTH 1067% · ELVN 971% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Omada Health Stock Pre-Market (+10%): Q4 Beat, Surprise Profit & Strong 2026 Guidance | 03/06/2026 | |
| Omada Health Earnings Notes | 12/16/2025 | |
| Is Omada Health Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.43 |
| Mkt Cap | 1.1 |
| Rev LTM | 785 |
| Op Inc LTM | -81 |
| FCF LTM | 62 |
| FCF 3Y Avg | 97 |
| CFO LTM | 202 |
| CFO 3Y Avg | 195 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.8% |
| Rev Chg 3Y Avg | 1.8% |
| Rev Chg Q | -1.3% |
| QoQ Delta Rev Chg LTM | -0.3% |
| Op Inc Chg LTM | 20.6% |
| Op Inc Chg 3Y Avg | 33.0% |
| Op Mgn LTM | -5.9% |
| Op Mgn 3Y Avg | -7.1% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 10.2% |
| CFO/Rev 3Y Avg | 11.7% |
| FCF/Rev LTM | 4.7% |
| FCF/Rev 3Y Avg | 5.8% |
Price Behavior
| Market Price | $19.66 | |
| Market Cap ($ Bil) | 1.2 | |
| First Trading Date | 06/06/2025 | |
| Distance from 52W High | -26.6% | |
| 50 Days | 200 Days | |
| DMA Price | $22.02 | $17.62 |
| DMA Trend | up | up |
| Distance from DMA | -10.7% | 11.6% |
| 3M | 1YR | |
| Volatility | 62.6% | 59.8% |
| Downside Capture | 167.44 | 160.15 |
| Upside Capture | 92.90 | 113.34 |
| Correlation (SPY) | 16.7% | 25.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.28 | 1.56 | 1.17 | 1.16 | 1.18 | 0.14 |
| Up Beta | -0.26 | 0.50 | 1.00 | 0.95 | 0.92 | -0.78 |
| Down Beta | 4.88 | 1.97 | 1.40 | 1.03 | 1.07 | 0.02 |
| Up Capture | 469% | 206% | 200% | 237% | 129% | 20% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 21 | 36 | 73 | 133 | 161 |
| Down Capture | 149% | 161% | 40% | 62% | 127% | 82% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 9 | 20 | 27 | 52 | 114 | 143 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMDA | |
|---|---|---|---|---|
| OMDA | -14.6% | 59.6% | -0.04 | - |
| Sector ETF (XLV) | 26.9% | 16.2% | 1.28 | 20.9% |
| Equity (SPY) | 17.7% | 13.0% | 0.98 | 25.0% |
| Gold (GLD) | 14.7% | 29.3% | 0.46 | -0.2% |
| Commodities (DBC) | 44.3% | 20.7% | 1.66 | -11.3% |
| Real Estate (VNQ) | 4.5% | 13.6% | 0.07 | 8.5% |
| Bitcoin (BTCUSD) | -25.9% | 44.8% | -0.54 | 16.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMDA | |
|---|---|---|---|---|
| OMDA | -3.7% | 64.0% | 0.03 | - |
| Sector ETF (XLV) | 6.8% | 15.2% | 0.26 | 18.5% |
| Equity (SPY) | 13.3% | 17.2% | 0.59 | 21.3% |
| Gold (GLD) | 19.2% | 18.8% | 0.83 | 2.4% |
| Commodities (DBC) | 10.8% | 19.6% | 0.43 | -11.4% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 6.1% |
| Bitcoin (BTCUSD) | 12.2% | 52.6% | 0.41 | 14.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMDA | |
|---|---|---|---|---|
| OMDA | -1.9% | 64.0% | 0.03 | - |
| Sector ETF (XLV) | 10.9% | 16.7% | 0.53 | 18.5% |
| Equity (SPY) | 15.5% | 17.9% | 0.73 | 21.3% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 2.4% |
| Commodities (DBC) | 8.5% | 18.1% | 0.38 | -11.4% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 6.1% |
| Bitcoin (BTCUSD) | 63.8% | 66.2% | 1.03 | 14.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 21.1% | 24.7% | 16.5% |
| 5/7/2026 | -9.6% | 1.1% | 9.0% |
| 3/5/2026 | 3.3% | 3.1% | -7.5% |
| 1/12/2026 | 4.6% | 4.6% | -26.5% |
| 11/6/2025 | -7.1% | -5.0% | -28.4% |
| 8/7/2025 | -2.3% | 4.9% | 23.5% |
| SUMMARY STATS | |||
| # Positive | 3 | 5 | 3 |
| # Negative | 3 | 1 | 3 |
| Median Positive | 4.6% | 4.6% | 16.5% |
| Median Negative | -7.1% | -5.0% | -26.5% |
| Max Positive | 21.1% | 24.7% | 23.5% |
| Max Negative | -9.6% | -5.0% | -28.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 21.1% | 24.7% | 16.5% |
| 5/7/2026 | -9.6% | 1.1% | 9.0% |
| 3/5/2026 | 3.3% | 3.1% | -7.5% |
| 1/12/2026 | 4.6% | 4.6% | -26.5% |
| 11/6/2025 | -7.1% | -5.0% | -28.4% |
| 8/7/2025 | -2.3% | 4.9% | 23.5% |
| SUMMARY STATS | |||
| # Positive | 3 | 5 | 3 |
| # Negative | 3 | 1 | 3 |
| Median Positive | 4.6% | 4.6% | 16.5% |
| Median Negative | -7.1% | -5.0% | -26.5% |
| Max Positive | 21.1% | 24.7% | 23.5% |
| Max Negative | -9.6% | -5.0% | -28.4% |
Recent Forward Guidance
Updated 8/7/2026Latest: Q2 2026 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 334.00 Mil | 337.00 Mil | 340.00 Mil | 3.4% | Raised | Guidance: 326.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 21.00 Mil | 24.00 Mil | 27.00 Mil | 41.2% | Raised | Guidance: 17.00 Mil for 2026 | |
Prior: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 322.00 Mil | 326.00 Mil | 330.00 Mil | 2.8% | Raised | Guidance: 317.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 14.00 Mil | 17.00 Mil | 20.00 Mil | 54.5% | Raised | Guidance: 11.00 Mil for 2026 | |
Q4 2025 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 312.00 Mil | 317.00 Mil | 322.00 Mil | 23.3% | Higher New | Actual: 257.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | Reported | 7.00 Mil | 11.00 Mil | 15.00 Mil | ||||
Q4 2025 Earnings Reported 1/12/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue | Reported | 72.00 Mil | 73.00 Mil | 74.00 Mil | ||||
| 2025 Revenue | Reported | 256.00 Mil | 257.00 Mil | 258.00 Mil | 1.6% | Raised | Guidance: 253.00 Mil for 2025 | |
Insider Activity
Updated 9/14/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 9142026 | 21.87 | 14,960 | 327,197 | 8,367,886 | Form |
| 2 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 9142026 | 21.86 | 6,800 | 148,640 | 3,801,378 | Form |
| 3 | Shao, Wei-Li | President | Direct | Sell | 9142026 | 21.85 | 4,036 | 88,206 | 6,454,021 | Form |
| 4 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 9112026 | 21.73 | 644 | 13,995 | 313,196 | Form |
| 5 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 9032026 | 23.62 | 21,572 | 509,465 | 9,726,905 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 9142026 | 21.87 | 14,960 | 327,197 | 8,367,886 | Form |
| 2 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 9142026 | 21.86 | 6,800 | 148,640 | 3,801,378 | Form |
| 3 | Shao, Wei-Li | President | Direct | Sell | 9142026 | 21.85 | 4,036 | 88,206 | 6,454,021 | Form |
| 4 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 9112026 | 21.73 | 644 | 13,995 | 313,196 | Form |
| 5 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 9032026 | 23.62 | 21,572 | 509,465 | 9,726,905 | Form |
| 6 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 8312026 | 25.00 | 1,108 | 27,700 | 4,680,225 | Form |
| 7 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 8112026 | 24.81 | 12,942 | 321,059 | 10,217,242 | Form |
| 8 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 8112026 | 21.85 | 8,628 | 188,522 | 8,999,163 | Form |
| 9 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 8052026 | 20.40 | 12,944 | 264,007 | 8,400,358 | Form |
| 10 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 7172026 | 24.01 | 12,150 | 291,774 | 4,495,695 | Form |
| 11 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 7152026 | 24.00 | 1,041 | 24,984 | 370,584 | Form |
| 12 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 7152026 | 24.00 | 5,800 | 139,206 | 4,493,210 | Form |
| 13 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 7082026 | 23.09 | 12,337 | 284,840 | 4,322,338 | Form |
| 14 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 7082026 | 22.76 | 23,263 | 529,501 | 4,261,158 | Form |
| 15 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 7062026 | 22.68 | 25,886 | 587,223 | 9,343,047 | Form |
| 16 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 7022026 | 23.00 | 637 | 14,651 | 355,143 | Form |
| 17 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 7022026 | 22.00 | 405 | 8,910 | 339,702 | Form |
| 18 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 7022026 | 22.00 | 300 | 6,600 | 2,538,998 | Form |
| 19 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 6302026 | 21.00 | 2,083 | 43,743 | 18,018 | Form |
| 20 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 6302026 | 21.07 | 17,950 | 378,167 | 2,431,414 | Form |
| 21 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 6302026 | 20.00 | 2,084 | 41,680 | 58,820 | Form |
| 22 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 6302026 | 19.89 | 33,000 | 656,449 | 2,652,831 | Form |
| 23 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 6262026 | 20.00 | 14,158 | 283,176 | 7,892,503 | Form |
| 24 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 6262026 | 19.00 | 300 | 5,701 | 7,767,808 | Form |
| 25 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 6262026 | 19.00 | 300 | 5,701 | 3,161,370 | Form |
| 26 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 6262026 | 19.01 | 2,800 | 53,239 | 7,777,845 | Form |
| 27 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 6262026 | 19.01 | 2,083 | 39,602 | 95,534 | Form |
| 28 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 6262026 | 19.02 | 2,600 | 49,445 | 3,169,404 | Form |
| 29 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 6242026 | 18.13 | 17,950 | 325,394 | 3,068,293 | Form |
| 30 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 6242026 | 18.00 | 2,083 | 37,494 | 127,944 | Form |
| 31 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 6182026 | 17.36 | 14,960 | 259,712 | 7,150,072 | Form |
| 32 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 6162026 | 17.23 | 6,800 | 117,184 | 3,226,154 | Form |
| 33 | Gracey, Craig | Chief Accounting Officer | Direct | Sell | 6162026 | 17.42 | 6,894 | 120,123 | 160,147 | Form |
| 34 | Shao, Wei-Li | President | Direct | Sell | 6162026 | 17.24 | 4,589 | 79,118 | 5,452,164 | Form |
| 35 | Shao, Wei-Li | President | Direct | Sell | 4102026 | 12.71 | 2,829 | 35,946 | 4,178,434 | Form |
| 36 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 3172026 | 13.94 | 1,884 | 26,263 | 2,795,137 | Form |
| 37 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 3112026 | 14.34 | 4,063 | 58,276 | 1,686,726 | Form |
| 38 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 1142026 | 15.95 | 40,796 | 650,774 | 2,020,212 | Form |
| 39 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 1142026 | 15.60 | 230,479 | 3,595,152 | 1,975,470 | Form |
| 40 | Shao, Wei-Li | President | Direct | Sell | 12302025 | 16.13 | 5,618 | 90,646 | 1,114,583 | Form |
| 41 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 12122025 | 15.37 | 4,211 | 64,705 | 884,542 | Form |
| 42 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 12122025 | 15.37 | 9,266 | 142,379 | 1,945,974 | Form |
Investor Activity (13F)
Updated Sep 27, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Omada Health — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.